A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

• Status: Completed
• Trial end date: 2017-06-10
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to monitor the safety profile of Trajenta Duo in Korean patients with type 2 diabetes mellitus (T2DM) in a routine clinical setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Collaborator: Eli Lilly and Company
• Treatments: Linagliptin

Criteria

Inclusion criteria:

Potential subjets must meet all of the following inclusion criteria to enter this trial:

1. No previous exposure to Trajenta, Trajenta Duo

2. Should have been started on Trajenta Duo in accordance with the approved label in Korea

3. No current participation in clinical trials

4. No metformin is inappropriate due to contraindications

5. Must sign on the data release consent form

Exclusion criteria:

Individuals with any of the following characteristics will not be able to enter this study:

1. Previous exposure to Trajenta, Trajenta Duo

2. Current participation in clinical trials

3. Patients for whom metformin is inappropriate due to contraindications